Welcome to our dedicated page for CAPRICOR THERAPEUTICS SEC filings (Ticker: CAPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Capricor Therapeutics filings document a Delaware biotechnology issuer developing cell and exosome-based therapeutics, including Deramiocel for Duchenne muscular dystrophy. Its 8-K reports record quarterly and annual financial results, FDA communications tied to the Deramiocel Biologics License Application, Regulation FD disclosures, and material-event reporting for litigation-related actions.
Proxy materials address board elections, executive compensation, equity awards, shareholder voting matters, and other governance disclosures. The filing record also identifies CAPR common stock, par value $0.001 per share, as a Nasdaq-listed security and provides formal disclosure around operating results, capital structure, and public-company status.
CAPR proposed sale notice: The filing lists 7,529 shares of Common Stock to be sold on 04/02/2026 in connection with an exercise of stock options for cash. It also reports recent 10b5-1 sales by Karimah Es Sabar of 53,735 and 61,265 shares on 04/01/2026 and 03/31/2026, respectively, with proceeds shown.
CAPRICOR THERAPEUTICS, INC. executive vice president and general counsel Karen Krasney reported an exercise-and-sell transaction in company stock. She exercised stock options covering a total of 25,000 shares of common stock at exercise prices of $1.39, $3.74 and $3.18 per share.
On the same day, she sold 25,000 shares of common stock at a weighted average price of $30.1174 per share, with individual trades ranging from $30.00 to $30.31. Following these transactions, she directly holds 30,547 shares of CAPRICOR common stock. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating the timing was set in advance.
CAPRICOR THERAPEUTICS director Karimah Es Sabar exercised stock options and sold the resulting shares in two days of trading. On March 31, 2026 and April 1, 2026, she exercised options to acquire a total of 115,000 shares of common stock at an exercise price of $4.86 per share and then sold all 115,000 shares in open-market transactions at weighted average prices of $30.1680 and $31.0268, respectively. Following these transactions, no shares from these exercised options remained held, and the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.
CAPRICOR THERAPEUTICS CFO Anthony Bergmann exercised stock options and sold shares in a planned transaction. He exercised options for 25,000 shares of Common Stock at $3.18 per share, then sold 25,000 shares of Common Stock at a weighted average price of $30.1261 per share.
The sale was completed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Bergmann directly holds 8,223 shares of Capricor Therapeutics common stock.
Capricor Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on June 4, 2026 at the company’s principal offices.
The Board has fixed the Record Date as April 6, 2026 and is asking shareholders to vote on the election of eight director nominees, ratification of the independent auditor, advisory votes on named executive officer compensation and frequency of say-on-pay votes, and an amendment regarding officer exculpation. The proxy statement includes director biographies, committee compositions, executive compensation disclosure for 2025 and related-party arrangements with Nippon Shinyaku, including upfront and milestone payments tied to distribution of Deramiocel.
Capricor Therapeutics EVP and General Counsel Karen Krasney exercised stock options to acquire 2,500 shares of common stock at an exercise price of $1.39 per share. These options were originally granted on January 3, 2017 and adjusted for a 1-for-10 reverse split and a later option reprice.
Following the exercise, Krasney directly holds 30,547 shares of Capricor common stock. The option grant vested in equal monthly installments, with 1/48th of the award vesting on the first day of each month beginning on February 1, 2017, and this filing reflects the full exercise of the remaining 2,500-share option position.
Capricor Therapeutics, Inc. details its strategy as a biotechnology company developing cell and exosome-based therapies, led by Deramiocel for Duchenne muscular dystrophy (DMD). A Biologics License Application for Deramiocel is under FDA review with a PDUFA target action date of August 22, 2026, following a Complete Response Letter and Class 2 resubmission.
The Phase 3 HOPE-3 trial in DMD met its primary endpoint, showing 54% slowing of progression on PUL v2.0 (p=0.029) and a key cardiac endpoint with 91% slowing of LVEF decline (p=0.041), alongside supportive functional and cardiac MRI data. Earlier HOPE-2 and HOPE-Duchenne studies and a long-term open-label extension also suggest preserved skeletal and cardiac function with an acceptable safety profile.
Capricor has built a global commercialization framework with Nippon Shinyaku, including U.S. and Japan distribution agreements and a European binding term sheet. Payments include a $30 million U.S. upfront plus multiple development and sales milestones (up to $605 million in U.S. sales milestones), a $12 million Japan upfront with up to about $89 million in milestones, and a European structure featuring a $20 million upfront and up to $715 million in potential milestones, all paired with double-digit revenue shares.